Your browser doesn't support javascript.
loading
Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors.
Kosari, Farhad; Disselhorst, Maria; Yin, Jun; Peikert, Tobias; Udell, Julia; Johnson, Sarah; Smadbeck, James; Murphy, Stephen; McCune, Alexa; Karagouga, Giannoula; Desai, Aakash; Schaefer-Klein, Janet; Borad, Mitesh J; Cheville, John; Vasmatzis, George; Baas, Paul; Mansfield, Aaron S.
Affiliation
  • Kosari F; Precision Cancer Therapeutics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
  • Disselhorst M; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Yin J; Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
  • Peikert T; Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.
  • Udell J; Precision Cancer Therapeutics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
  • Johnson S; Precision Cancer Therapeutics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
  • Smadbeck J; Precision Cancer Therapeutics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
  • Murphy S; Precision Cancer Therapeutics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
  • McCune A; Precision Cancer Therapeutics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
  • Karagouga G; Precision Cancer Therapeutics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
  • Desai A; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
  • Schaefer-Klein J; Precision Cancer Therapeutics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
  • Borad MJ; Precision Cancer Therapeutics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota; Department of Medical Oncology, Mayo Clinic, Phoenix, Arizona.
  • Cheville J; Precision Cancer Therapeutics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Vasmatzis G; Precision Cancer Therapeutics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
  • Baas P; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Mansfield AS; Precision Cancer Therapeutics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota. Electronic address: mansfield.aaron@mayo.edu.
J Thorac Oncol ; 17(3): 446-454, 2022 03.
Article in En | MEDLINE | ID: mdl-34800701
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mesothelioma, Malignant / Lung Neoplasms / Mesothelioma Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Thorac Oncol Year: 2022 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mesothelioma, Malignant / Lung Neoplasms / Mesothelioma Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Thorac Oncol Year: 2022 Document type: Article Country of publication: